This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|September 7, 2018
ICS Opens Logistics Distribution Center in Ohio
Author(s)BioPharm International Editors
ICS distribution center will serve manufacturers of specialty medications, biosimilars, and cell and gene therapies.
Advertisement
ICS, a part of AmerisourceBergen, announced on Aug. 29, 2018 the opening of a third-party logistics pharmaceutical distribution center in Lockbourne, OH, which will serve as the flagship location. The largest facility in the company’s network, the 350,000-sq.-ft. distribution center will feature operations tools and technology and a logistics system to accommodate products of different sizes, temperatures, and storage needs. The facility is a certified Foreign Trade Zone Solution, which allows manufacturers to store products awaiting FDA approval in a duty-free environment.
The emergence of high-value products such as cell and gene therapies has increased the demand for rigorous and customized storage solutions, ICS reported in a press statement. The distribution center will enable the company to meet the needs for time-sensitive and ultra-frozen capabilities.
With the addition of the new facility in Ohio, ICS reports it has more than 925,000-sq.-ft .of managed warehouse at four locations within the United States.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5